 |
市场调查报告书
商品编码
1766592
中轴型脊椎关节炎市场：按类型、按治疗剂、按给药途径、按产品类型、按性别、按分销管道、按最终用户、按地区Axial Spondyloarthritis Market, By Type, By Therapeutics, By Route of Administration, By Product Type, By Gender, By Distribution Channel, By End User, By Geography |
||||||
预计 2025 年中轴型脊椎关节炎市场规模为 44.1 亿美元，到 2032 年将达到 70.1 亿美元，2025 年至 2032 年的复合年增长率为 6.85%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 44.1亿美元 |
| 效能数据 | 从2020年到2024年 | 预测期 | 2025年至2032年 |
| 预测期：2025-2032年复合年增长率： | 6.85% | 2032年价值预测 | 70.1亿美元 |
中轴型脊椎关节炎 (axSpA) 是一种慢性发炎性风湿性疾病，主要影响脊椎和骶髂关节，其特征是进行性结构损伤、功能障碍以及对患者生活品质的严重影响。全球中轴型脊椎关节炎市场涵盖了全面的治疗性介入、诊断工具和管理解决频谱，旨在应对这种影响全球数百万人的衰弱性疾病。该市场包括放射学僵直性脊椎炎(AS) 和非放射学腋窝脊椎关节炎 (nr-axSpA)，反映了人们对该疾病分类和进展的不断理解。由于医疗专业人员和患者意识的提高，以及早期诊断和生物目标的进步，市场正见证显着的成长势头。
肿瘤坏死因子 (TNF) 抑制剂、白细胞介素-17 (IL-17) 抑制剂和新兴的Janus激酶 (JAK) 抑制剂是治疗的主流，为患者提供改善的症状管理和潜在的疾病逆转。不断增加的医疗保健支出、日益增长的自体免疫疾病盛行率、透过先进的影像技术提高的诊断能力以及强劲的製药研发活动共同推动着市场扩张，使全球中轴型脊椎关节炎市场成为更广泛的风湿病治疗行业中的一个重要部分。
市场动态
全球中轴型脊椎关节炎市场受多种强劲驱动因素驱动，这些因素增强了市场成长前景并带来了治疗进步的机会。疾病盛行率的上升，尤其是在20-40岁年轻族群中，是成长的主要催化剂，因为据估计，全球0.7%的人口患有中轴型脊椎关节炎，这带来了对有效治疗方案的巨大需求。透过先进的影像技术（包括磁振造影造影(MRI) 和专门的生物标记），提高了人们对该疾病的认识并提升了诊断能力，从而能够早期发现和干预该疾病，显着扩大了可治疗的患者群体。强大的创新生物製药和标靶化缓解疾病抗风湿药物 (tsDMARDs) 产品线，可提供更高的疗效和个人化的治疗方案，并透过高端定价和改善的患者治疗效果推动市场扩张。
然而，由于生物製药治疗费用可能超过每位患者每年5万美元，市场成长面临许多限制因素，包括价格敏感型市场供应有限以及全球医疗保健体系的报销挑战。新疗法严格的核准流程，加上繁琐的临床试验要求，可能导致开发时间延长、开发成本上升，可能阻碍新兴疗法的市场准入。此外，axSpA的诊断复杂，常导致误诊或延误诊断，阻碍及时启动治疗和市场渗透。儘管如此，新兴经济体医疗基础设施的不断扩张、医疗支出的不断增加，以及经济高效的生物仿製药作为品牌生技药品替代品的日益普及，正在创造巨大的机会，因为它们使先进疗法的可及性更加民主化，并有望推动不同地区和经济领域的市场扩张。
本研究的主要特点
- 本报告对全球腋窝脊椎关节炎市场进行了详细分析，并提供了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设 2024 年为基准年。
- 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
- 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球中轴型脊椎关节炎市场的主要企业概况。
- 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
- 本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 可以透过用于分析全球中轴型脊椎关节炎市场的各种策略矩阵来促进相关人员的决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 驱动程式
- 限制因素
- 机会
- 影响分析
- 主要进展
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
- 产业趋势
4. 2020 年至 2032 年全球中轴型脊椎关节炎市场（按类型）
- 僵直性脊椎炎
- 非放射学中轴型脊椎关节炎
5. 2020 年至 2032 年全球中轴型脊椎关节炎市场（依治疗剂划分）
- 非类固醇消炎剂（NSAID）
- 生物缓解疾病抗风湿药（bDMARDs）
- 传统 DMARD 药物
- 其他（如皮质类固醇）
6. 全球中轴型脊椎关节炎市场（依给药途径），2020 年至 2032 年
- 口服
- 皮下注射（SC）
- 静脉输液
7. 2020 年至 2032 年全球中轴型脊椎关节炎市场（依产品类型）
- 品牌
- 非专利的
8. 2020 年至 2032 年全球中轴型脊椎关节炎市场（依性别划分）
- 女士
- 男性
9. 全球中轴型脊椎关节炎市场（依通路划分），2020 年至 2032 年
- 医院药房
- 零售药局
- 网路药局
第 10 章。 2020 年至 2032 年全球中轴型脊椎关节炎市场（依最终用户划分）
- 医院
- 专科诊所
- 门诊手术中心
- 復健物理治疗中心
- 其他（学术研究机构等）
第 11 章。 2020 年至 2032 年按地区分類的全球中轴型脊椎关节炎市场
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 南非
- 北非
- 中部非洲
第十二章竞争格局
- AbbVie
- Amgen
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
- Novartis
- Pfizer
- Roche
- UCB
- Eli Lilly and Company
- Merck & Co.
- Gilead Sciences
- Sanofi
- Takeda
- Biogen
- Astellas Pharma
第 13 章分析师建议
- 机会
- 分析师观点
- Coherent Opportunity Map
第十四章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Axial Spondyloarthritis Market is estimated to be valued at USD 4.41 Bn in 2025 and is expected to reach USD 7.01 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.85% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.41 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.85% | 2032 Value Projection: | USD 7.01 Bn |
Axial Spondyloarthritis (axSpA) represents a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints, characterized by progressive structural damage, functional impairment, and significant impact on patients' quality of life. The global axial spondyloarthritis market encompasses a comprehensive spectrum of therapeutic interventions, diagnostic tools, and management solutions designed to address this debilitating condition that affects millions worldwide. The market includes both ankylosing spondylitis (AS), the radiographic form, and non-radiographic axial spondyloarthritis (nr-axSpA), reflecting the evolving understanding of disease classification and progression. With increasing awareness among healthcare professionals and patients, coupled with advancements in early diagnosis and targeted biologics, the market has witnessed substantial growth momentum.
The therapeutic landscape is dominated by tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhibitors, and emerging Janus kinase (JAK) inhibitors, offering patients improved symptom management and disease modification potential. Rising healthcare expenditure, growing prevalence of autoimmune disorders, enhanced diagnostic capabilities through advanced imaging techniques, and robust pharmaceutical research and development activities are collectively driving market expansion, positioning the global axial spondyloarthritis market as a critical segment within the broader rheumatology therapeutics industry.
Market Dynamics
The global axial spondyloarthritis market is propelled by several compelling drivers that collectively enhance market growth prospects and therapeutic advancement opportunities. Increasing disease prevalence, particularly among young adults aged 20-40 years, serves as a primary growth catalyst, with an estimated 0.7% of the global population affected by axSpA, creating substantial demand for effective treatment solutions. Growing awareness and improved diagnostic capabilities through advanced imaging technologies, including magnetic resonance imaging (MRI) and specialized biomarkers, enable earlier disease detection and intervention, expanding the treatable patient population significantly. The robust pipeline of innovative biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) offers enhanced therapeutic efficacy and personalized treatment approaches, driving market expansion through premium pricing and improved patient outcomes.
However, market growth faces notable restraints including high treatment costs associated with biologic therapies, which can exceed USD 50,000 annually per patient, limiting accessibility in price-sensitive markets and creating reimbursement challenges for healthcare systems globally. Stringent regulatory approval processes for new therapeutic agents, coupled with extensive clinical trial requirements, result in prolonged development timelines and increased development costs, potentially hindering market entry for emerging treatments. Additionally, the complex nature of axSpA diagnosis, often involving years of misdiagnosis or delayed diagnosis, creates barriers to timely treatment initiation and market penetration. Nevertheless, significant opportunities emerge through expanding healthcare infrastructure in developing economies, increasing healthcare spending, and growing acceptance of biosimilar medications that offer cost-effective alternatives to branded biologics, potentially democratizing access to advanced treatments and expanding market reach across diverse geographic regions and economic segments.
Key Features of the Study
- This report provides in-depth analysis of the global axial spondyloarthritis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global axial spondyloarthritis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Novartis, Pfizer, Roche, UCB, Eli Lilly and Company, Merck & Co., Gilead Sciences, Sanofi, Takeda, Biogen, and Astellas Pharma
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global axial spondyloarthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global axial spondyloarthritis market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Ankylosing Spondylitis
- Non-radiographic Axial Spondyloarthritis
- Therapeutics Insights (Revenue, USD Bn, 2020 - 2032)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Meloxicam
- Naproxen
- Celecoxib
- Diclofenac
- Others (Indomethacin, etc.)
- Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
- TNF inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Others (Golimumab, etc.)
- IL-17 inhibitors
- Secukinumab
- Ixekizumab
- Others (Bimekizumab, etc.)
- JAK inhibitors
- Tofacitinib
- Upadacitinib
- Conventional DMARDs
- Sulfasalazine
- Methotrexate
- Others (Corticosteroids, etc.)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Subcutaneous (SC) Injections
- Intravenous (IV) Infusions
- Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Female
- Male
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Rehabilitation & physiotherapy centers
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie
- Amgen
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
- Novartis
- Pfizer
- Roche
- UCB
- Eli Lilly and Company
- Merck & Co.
- Gilead Sciences
- Sanofi
- Takeda
- Biogen
- Astellas Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Axial Spondyloarthritis Market, By Type
- Global Axial Spondyloarthritis Market, By Therapeutics
- Global Axial Spondyloarthritis Market, By Route of Administration
- Global Axial Spondyloarthritis Market, By Product Type
- Global Axial Spondyloarthritis Market, By Gender
- Global Axial Spondyloarthritis Market, By Distribution Channel
- Global Axial Spondyloarthritis Market, By End User
- Global Axial Spondyloarthritis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Axial Spondyloarthritis Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-radiographic Axial Spondyloarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Axial Spondyloarthritis Market, By Therapeutics, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Meloxicam
- Naproxen
- Celecoxib
- Diclofenac
- Others (Indomethacin, etc.)
- Meloxicam
- Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- TNF inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Others (Golimumab, etc.)
- IL-17 inhibitors
- Secukinumab
- Ixekizumab
- Others (Bimekizumab, etc.)
- JAK inhibitors
- Tofacitinib
- Upadacitinib
- TNF inhibitors
- Conventional DMARDs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sulfasalazine
- Methotrexate
- Sulfasalazine
- Others (Corticosteroids, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Axial Spondyloarthritis Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subcutaneous (SC) Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous (IV) Infusions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Axial Spondyloarthritis Market, By Product Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Axial Spondyloarthritis Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Axial Spondyloarthritis Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Axial Spondyloarthritis Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rehabilitation & physiotherapy centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Axial Spondyloarthritis Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
